Quintrio
Home

PHARMACEUTICAL PREPARATIONS

PERRIGO COMPANY PLC

PRGO

Perrigo is a pure-play consumer healthcare product manufacturer and distributor. In North America (two-thirds of total sales), the firm's product mix centers on private-label consumer health goods sold to major retailers such as Walmart, Amazon.com, Costco, and CVS. It plays in a number of over-the-counter categories including pain, skincare, women's health, and nutrition. Perrigo also competes in Europe, Australia, and parts of Asia, where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.

Last trade $15.92
Day change -$0.26 (-1.61%)
Day range $15.82 – $16.57
Volume 745,229
Market cap $2.25B

Open XNYS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$2.25B
Price / earnings
—
Price / book
0.92×
Price / sales
0.55×
EV / sales
1.25×
EV / EBITDA
9.61×

Profitability

Earnings per share
-$12.75
Return on assets
-23.64%
Return on equity
-72.51%
Dividend yield
7.13%

Liquidity and leverage

Debt / equity
1.35×
Current ratio
2.35×
Quick ratio
1.36×
Cash ratio
0.43×

Cash flow

Price / cash flow
9.33×
Price / free cash flow
13.35×
Free cash flow
$168.2M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for PRGO, quarterly periods
Line itemQ3 FY2026 Sep 26, 2026Q2 FY2026 Jun 27, 2026Q1 FY2026 Mar 28, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 27, 2025Q2 FY2025 Jun 28, 2025Q1 FY2025 Mar 29, 2025Q4 FY2024 Dec 31, 2024
Revenue$988.6M$1.02B$969.2M$1.11B$1.04B$1.06B$1.04B$1.14B
Cost of revenue$667.8M$708.9M$643.7M$747.4M$666.2M$693.4M$651.6M$752.4M
Gross profit$320.8M$313.9M$325.5M$362.2M$377.1M$362.9M$392.3M$385.9M
Selling, general and administrative$271.7M$251.2M$267.3M$255.9M$245.7M$273.1M$281.2M$234.8M
Research and development$21.9M$23.7M$24.6M$21.8M$24.9M$22M$26.7M$27.8M
Total operating expenses$297.7M$290.3M$697.8M$1.65B$304.5M$317.5M$345.4M$271.7M
Operating income$23.1M$23.6M-$372.3M-$1.29B$72.6M$45.4M$46.9M$114.2M
Interest expense-$37.9M-$38.4M-$40.8M-$43.3M-$40.6M-$39.6M-$39M-$43.1M
Income before taxes-$18.1M$105.4M-$408.5M-$1.33B$22.4M$3.2M$8.3M$70M
Income taxes-$3.8M$16.9M-$18.7M$82.9M$9.7M$3.7M$8.2M$111.5M
Net income-$27.5M$74.5M-$398.5M-$1.42B$7.5M-$8.4M-$6.4M-$44.5M
Net income attributable to common shareholders-$27.5M$74.5M-$398.5M-$1.42B$7.5M-$8.4M-$6.4M-$44.5M
EBITDA$109M$134.8M$116.9M$170.3M$178.8M$141.9M$159.3M$245.1M
Basic earnings per share-$0.20$0.54-$2.87-$10.16$0.05-$0.06-$0.05-$0.32
Diluted earnings per share-$0.20$0.53-$2.87-$10.19$0.05-$0.06-$0.05-$0.32

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
The Motley Fool

Perrigo: 3 Key Takeaways for Long-Term Investors

Perrigo announced an agreement to divest its infant formula business to streamline operations and improve margins. The company is capitalizing on e-commerce momentum, with online sales reaching 22% of U.S. volume (up from 13% in 2022). Despite cautious retailer ordering, Perrigo gained market share in store brands and European health products, positioning itself as a more focused consumer self-care company.

Zacks Investment Research

Perrigo (PRGO) Surpasses Q3 Earnings Estimates

Perrigo (PRGO) reported Q3 2026 earnings of $0.60 per share, beating consensus estimates of $0.56, but revenues missed expectations at $988.6 million versus $990.2 million consensus. Despite outperforming the S&P 500 by 2.2% year-to-date, the company received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revision trends. The Medical-Products industry ranks in the bottom 37% of Zacks industries, suggesting headwinds ahead.

Zacks Investment Research

Stryker (SYK) Q3 Earnings and Revenues Lag Estimates

Stryker reported Q3 2026 earnings of $3.52 per share, missing consensus estimates of $3.56, with revenues of $6.52 billion also falling short of expectations. The company received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revisions. Stryker has underperformed the S&P 500 by 26.6% year-to-date, and the Medical Products industry ranks in the bottom 38% of Zacks industries.

Zacks Investment Research

Earnings Preview: Perrigo (PRGO) Q3 Earnings Expected to Decline

Perrigo is expected to report Q3 2026 earnings of $0.56 per share (down 30% YoY) and revenues of $990.45 million (down 5.1% YoY) on November 4. With a negative Earnings ESP of -11.24% and a Zacks Rank #4, the stock appears unlikely to beat consensus estimates despite a strong historical track record of beating expectations in 3 of the last 4 quarters.

Zacks Investment Research

Abbott (ABT) Misses Q3 Earnings Estimates

Abbott reported Q3 2026 earnings of $1.42 per share, missing the consensus estimate of $1.43, though revenues of $13.01 billion exceeded expectations. The company has underperformed the S&P 500 by 18.2% year-to-date. Despite the earnings miss, Abbott maintains a Zacks Rank #2 (Buy) rating based on favorable estimate revision trends. The Medical-Products industry ranks in the bottom 36% of Zacks industries.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily
Declared upcoming dividend $0.29 per share
Declared
Oct 29, 2026
Ex-dividend
Nov 27, 2026
Pay date
Dec 15, 2026
Ex-dividendAmount / sharePay dateType
Aug 28, 2026$0.29Sep 15, 2026recurring
May 29, 2026$0.29Jun 16, 2026recurring
Mar 2, 2026$0.29Mar 24, 2026recurring
Nov 28, 2025$0.29Dec 16, 2025recurring
Aug 29, 2025$0.29Sep 16, 2025recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.